Bispecific Antibody Selection in Multiple Myeloma

Opinion
Video

Clinical insights on selecting the right bispecific antibody for the right patient and an overview of barriers seen in community practice.

Recent Videos
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
Although a similar proportion achieved MRD negativity at the 10 to the –6 power, not enough studies have analyzed MRD at this level for multiple myeloma.
Unique toxicities presented with talquetamab tend to get progressively better as the treatment course continues, according to Prerna Mewawalla, MD.
Prophylactic steroid or tocilizumab use may help in preventing CRS in patients undergoing treatment with bispecific antibodies for multiple myeloma.
Related Content
The most common any-grade AE was diarrhea, occurring in 74.0% of the experimental group and 72.2% of the standard group.

Antiemetic Regimen Limits Chemo-Induced Nausea/Vomiting in Multiple Myeloma

Tim Cortese
October 6th 2025
Article

Patients with multiple myeloma who received palonosetron, dexamethasone, aprepitant, and olanzapine achieved a 44.1% CR rate across all study phases.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Treatment with anito-cel shows a predictable and manageable safety profile among those with relapsed/refractory multiple myeloma in the iMMagine-1 trial.

Anito-Cel Yields Enduring Efficacy in Relapsed/Refractory Multiple Myeloma

Russ Conroy
September 30th 2025
Article

Treatment with anito-cel shows a predictable and manageable safety profile among those with relapsed/refractory multiple myeloma in the iMMagine-1 trial.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

The median PFS was not reached with daratumumab-lenalidomide maintenance after a median follow-up of 49 months in those with multiple myeloma.

Dara-KRd Regimen Displays Prolonged PFS in Newly Diagnosed Multiple Myeloma

Roman Fabbricatore
September 22nd 2025
Article

The median PFS was not reached with daratumumab-lenalidomide maintenance after a median follow-up of 49 months in those with multiple myeloma.

CEPHEUS Highlights Efficacious, Safe Regimen for Transplant-Ineligible/Deferred Multiple Myeloma

CEPHEUS Highlights Efficacious, Safe Regimen for Transplant-Ineligible/Deferred Multiple Myeloma

ONCOLOGY Staff
September 21st 2025
Article

Recent advancements in multiple myeloma treatment highlight the efficacy of daratumumab combined with VRd, showcasing improved outcomes and tolerability.